Travere Therapeutics Announces Topline Results from Two-Year

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with... | May 1, 2023

Related Keywords

United States , Jula Inrig , Naomi Eichenbaum , Nivi Nehra , Deric Dube , Corporate Communications , Nasdaq , Travere Therapeutics Inc , European Union , Exchange Commission On , Company Annual Report On Form , European Medicines Agency , Travere Therapeutics , Dual Endothelin Angiotensin Receptor Antagonist , New Drug Application , Conditional Marketing Authorization , Efficacy Endpoints , Two Year Exploratory Endpoints , Important Safety , Endothelin Receptor Antagonists , Upper Limit , Fetal Toxicity , Kidney Injury , Angiotensin System , Acid Reducing Agents , Steroidal Anti Inflammatory Agents , Including Selective , Increasing Serum Potassium , Reproductive Potential , Full Prescribing Information , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Nc Stock Exchange , News , Information , Press Release , The , Duplex , Study , Kid , Lot , Chieve , Primary , Efficacy , Egfr , Slope , Ndpoint , Dover , 08 , Eeks , F , Treatment , Secondary , End , Topline , Exploratory , Endpoints , Xtrended , Favorably , Or , Sparsentan , Reatment Tvtx Us89422g1076 ,